Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

Rhea-AI Summary

Alebund Pharmaceuticals (NYSE:DVA) granted R1 Therapeutics exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China and received a substantial non-dilutive equity stake in R1.

The deal includes up to low triple‑digit millions in milestone payments, tiered royalties in the low double‑digit percent range, and a planned global Phase 2b MRCT starting later this year.

Positive

• Exclusive license for AP306 outside Greater China
• Deal includes up to low triple‑digit $M in milestone payments
• Tiered royalties in the low double‑digit % on net sales
• Alebund holds substantial non‑dilutive equity in R1
• Planned global Phase 2b MRCT to initiate later in 2026

Negative

• Commercial rights granted outside Greater China limit Alebund's direct sales upside
• R1 will fund and lead global development, reducing Alebund's control over programs

News Market Reaction – DVA

+1.19%

1 alert

+1.19% News Effect

+$117M Valuation Impact

$9.94B Market Cap

0.0x Rel. Volume

On the day this news was published, DVA gained 1.19%, reflecting a mild positive market reaction. This price movement added approximately $117M to the company's valuation, bringing the market cap to $9.94B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Series A financing: $77.5M

1 metrics

Series A financing $77.5M R1 Therapeutics oversubscribed Series A round

Market Reality Check

Price: $149.91 Vol: Volume 1,040,703 is sligh...

normal vol

$149.91 Last Close

Volume Volume 1,040,703 is slightly above the 20-day average of 890,725, indicating elevated trading interest before this announcement. normal

Technical Price at 148.22 is trading above the 200-day MA of 131.01, reflecting a longer-term upward trend into this news.

Peers on Argus

Before this collaboration news, DVA was down 1.66%, while peers like ENSG, CHE, ...

Before this collaboration news, DVA was down 1.66%, while peers like ENSG, CHE, OPCH, AMED, and UHS also showed negative moves (from -0.03% to -1.40%), suggesting broader weakness in medical care facilities rather than a DVA‑specific move.

Historical Context

5 past events · Latest: Feb 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Conference participation	Neutral	-0.2%	Participation in TD Cowen health care conference fireside chat with management.
Feb 02	Earnings results	Positive	+21.2%	Reported Q4 and full‑year 2025 revenues and EPS plus 2026 guidance and capital actions.
Feb 02	Strategic investment	Positive	+1.7%	DaVita and Ares invested in Elara Caring to expand kidney‑focused in‑home care.
Jan 21	Earnings call setup	Neutral	+2.3%	Scheduled Q4 2025 earnings call and outlined webcast and dial‑in access.
Jan 06	Board appointment	Positive	+0.7%	Tolion Health AI appointment of Gregory J. Moore to board, highlighting DaVita linkage.

Pattern Detected

Recent DaVita news spanning earnings, strategic investments, and conferences has generally coincided with modestly positive or stable share price reactions, with earnings producing the strongest move.

Recent Company History

Over the past few months, DaVita has reported solid Q4 and full‑year 2025 financials, including revenues of $3.620B for Q4 and $13.643B for 2025, plus adjusted diluted EPS of $3.40 and $10.78. That earnings release coincided with a 21.17% move. The company also announced a strategic investment in Elara Caring to expand kidney‑focused home care, and participated in investor conferences. Against this backdrop, today’s AP306‑related collaboration highlights continued ecosystem activity around kidney care where DaVita is a key provider and investor.

Market Pulse Summary

This announcement highlights a collaboration around AP306, a first‑in‑class therapy candidate for hy...

Analysis

This announcement highlights a collaboration around AP306, a first‑in‑class therapy candidate for hyperphosphatemia in chronic kidney disease patients on dialysis, with R1 Therapeutics funding and leading global development, backed by a $77.5M Series A. For DaVita, a major kidney care provider, the deal underscores ongoing ecosystem innovation in CKD treatment. Investors may focus on trial progress for the planned global Phase 2b MRCT, regulatory milestones, and how such therapies could integrate with dialysis‑center care and existing service models.

Key Terms

hyperphosphatemia, chronic kidney disease, pan-phosphate transporter inhibitor, dialysis, +4 more

8 terms

hyperphosphatemia medical

"for the treatment of hyperphosphatemia in patients with chronic kidney disease"

An elevated level of phosphate in the blood, often caused by reduced kidney function or certain medications, that can harm bones, blood vessels and organs if untreated. Investors should care because prevalence, safety concerns and regulatory scrutiny around treatments or diagnostics for this condition can drive demand, affect clinical trial outcomes, influence healthcare spending and change a company’s revenue and risk profile—similar to how a common road hazard can change demand for safety products.

chronic kidney disease medical

"hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis"

Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.

pan-phosphate transporter inhibitor medical

"AP306 is a first-in-class pan-phosphate transporter inhibitor in development"

A pan-phosphate transporter inhibitor is a drug that blocks a broad set of proteins cells use to move phosphate into and out of tissues. Think of it as turning down multiple small faucets that supply phosphate to cells; by limiting that flow the drug can change cell growth, mineral balance and signaling. Investors care because these agents target conditions where phosphate control matters (for example kidney disease, some cancers or metabolic disorders), so success or safety issues in trials can strongly affect a drug’s market potential and regulatory risk.

dialysis medical

"chronic kidney disease (CKD) receiving dialysisAlebund grants exclusive rights"

Dialysis is a medical treatment that cleans the blood and removes extra fluid when the kidneys can no longer do that job, using a machine or a filtered solution much like an external water filter for the body. It matters to investors because dialysis creates steady demand for specialized clinics, machines, supplies and drugs, driving predictable revenue streams, capital and regulatory risks, and long-term patient volumes that affect healthcare company valuations.

royalties financial

"tiered royalties in the low double-digit percentage range based on net sales"

Payments made to the owner of an asset or intellectual property each time that asset is used or a product is sold, often calculated as a percentage of sales or a set amount per unit. Royalties matter to investors because they create predictable, ongoing income streams and affect a company’s cash flow and valuation—like a landlord collecting rent or an author getting a steady cut whenever a book is sold.

Phase 2b medical

"including a global Phase 2b multi-regional clinical trial ("MRCT") in the U.S."

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

multi-regional clinical trial medical

"global Phase 2b multi-regional clinical trial ("MRCT") in the U.S. and China"

A multi-regional clinical trial tests a drug or medical device at study sites in several different countries or geographic regions at the same time, so results reflect how it works across diverse populations and health systems. For investors, these trials matter because they can speed enrollment, strengthen regulatory credibility and market access across territories, but also increase complexity, cost and timing—like testing a car in multiple climates to prove it works everywhere.

Series A financing financial

"company that recently completed an oversubscribed Series A financing of $77.5M"

A Series A financing is an early formal round of investment in a growing private company where outside investors provide significant capital in exchange for a stake in the business. It matters to investors because it helps set the company's market value, shows that professional backers believe the business can scale, and determines how much ownership current holders keep—similar to bringing in a partner to fund and accelerate a first big expansion.

AI-generated analysis. Not financial advice.

AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis

Alebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therapeutics, a newly launched company backed by leading global kidney care providers and life sciences strategic and venture capital investors

The collaboration includes potential milestone payments of up to low triple-digit millions of U.S. dollars and tiered royalties in the low double-digit percentage range based on net sales of AP306 in the licensed territory

Alebund holds a substantial non-dilutive equity interest in R1, with the opportunity to participate in future commercial upside through dividends

SHANGHAI, March 17, 2026 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), a leading renal-focused biopharmaceutical company, today announced that it has entered into licensing and equity agreements (the "Agreements") with R1 Therapeutics, Inc. ("R1"). R1 is a newly launched clinical-stage biotechnology company that recently completed an oversubscribed Series A financing of $77.5M. R1 is backed by major global kidney care providers, DaVita, one of the largest kidney care providers globally, and U.S. Renal Care, the largest privately held dialysis provider in the United States and a syndicate of leading global venture capital investors.

Under the Agreements, Alebund has granted R1 an exclusive license to develop, manufacture, and commercialize AP306 outside Greater China (the "R1 Territory"). As part of the transaction, the aggregate financial terms include development, regulatory and commercial milestone payments of up to low triple-digit millions of U.S. dollars, and Alebund will share in the economics of AP306's success in the R1 Territory through tiered royalty payments in the low double-digit percentage range on net sales. In addition, Alebund holds a substantial non-dilutive equity interest in R1, with the opportunity to participate in future commercial upside through dividends. R1 will fund and lead the global clinical development of AP306, with Alebund as a collaborative development partner, including a global Phase 2b multi-regional clinical trial ("MRCT") in the U.S. and China planned to initiate later this year. Alebund and R1 will work together to accelerate the global development of AP306.

Gavin Xia, Ph.D., Co-Founder and CEO of Alebund Pharmaceuticals, commented:

"This collaboration validates the global potential of AP306 and represents an important milestone for Alebund. By partnering with R1, global kidney care providers, and financial investors, we can accelerate AP306's global development. With the support of R1, DaVita and U.S. Renal Care, we are well-positioned to capture the significant market potential in the United States. We look forward to working with the R1 team to bring this potentially transformative therapy to patients worldwide."

Krishna Polu, M.D., Co-Founder, President and CEO of R1 Therapeutics, commented:

"We are thrilled to launch R1 with the backing of world-class investors who share our conviction in the potential of AP306 to fundamentally change how hyperphosphatemia is managed. AP306 represents a new mechanistic approach - blocking the active transport of phosphorus rather than relying on traditional phosphate binding - and the Phase 2a data published in Kidney International Reports demonstrate compelling efficacy and tolerability. We look forward to advancing the global Phase 2b program in collaboration with Alebund and bringing AP306 to patients around the world."

About AP306

AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis. Unlike conventional phosphate binders, AP306 works by inhibiting the active transport of phosphorus through three key phosphate transporters (NaPi-IIb, PiT-1, and PiT-2) in the gastrointestinal tract, representing a fundamentally new mechanism of action for managing hyperphosphatemia. AP306 was originally discovered by Chugai Pharmaceuticals Co., Ltd. and subsequently licensed to Alebund Pharmaceuticals, which has conducted clinical development of the compound, including a completed Phase 2a study in hemodialysis patients. Results published in Kidney International Reports demonstrated significant reduction in serum phosphate levels with good safety and tolerability. Data from the Phase 2a study has also been presented at the 61st European Renal Association (ERA) Annual Congress.

About R1 Therapeutics

R1 Therapeutics is a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease. Its lead program, AP306, targets hyperphosphatemia in patients with chronic kidney disease on dialysis, a condition associated with serious bone and cardiovascular complications and poorer outcomes when phosphate remains uncontrolled. AP306 is a first-in-class pan-phosphate active transport inhibitor designed to block three key phosphate transporters in the gut, with the potential to deliver rapid and effective phosphate lowering with a significantly reduced treatment burden. R1 has licensed exclusive global rights outside Greater China to AP306 from Alebund Pharmaceuticals and is advancing a global Phase 2b development program. R1 launched with an oversubscribed $77.5 million Series A financing in March 2026 co-led by Abingworth, DaVita Venture Group, and F-Prime, with participation from Curie.Bio, SymBiosis, and U.S. Renal Care. For more information, visit www.r1therapeutics.com and follow R1 on LinkedIn.

About Alebund Pharmaceuticals

Alebund Pharmaceuticals is a global leading renal-focused biopharmaceutical company with a vertically integrated platform encompassing R&D, manufacturing, and commercialization. The Company possesses the most comprehensive innovative renal portfolio in terms of indication coverage, with seven drug candidates and one commercialized product (Mircera®) targeting a broad range of renal indications including CKD complications (hyperphosphatemia, renal anemia), IgA nephropathy, diabetic kidney disease, FSGS, and ADPKD. Alebund holds global rights for its core pipeline assets, including AP301 (a best-in-class oral phosphate binder currently in global Phase 3), AP306, AP303 (a first-in-class dual PPAR agonist with FDA Orphan Drug Designation for ADPKD), and AP308 (a first-in-class IgA protease). The Company has completed construction of its manufacturing facility in Yangzhou, China, and has established a dedicated in-house commercialization team in China.

About DaVita

DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 25 years. DaVita cares for patients at every stage and setting along their kidney health journey-from slowing the progression of kidney disease to helping support transplantation. This includes ensuring they are supported at home, in dialysis centers, in the hospital and in skilled nursing facilities. As of December 31, 2025, DaVita served approximately 295,000 patients at 3,242 outpatient dialysis centers, of which 2,657 centers were located in the United States and 585 centers were located in 14 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

About U.S. Renal Care

U.S. Renal Care, the largest privately held and fastest-growing dialysis provider in the nation, partners with nephrologists to care for more than 37,000 people living with kidney disease across 32 states in the U.S. Since 2000, U.S. Renal Care has been a leader in clinical quality, innovation, and operational excellence - delivering the best experience and outcomes for its patients. Visit USRenalCare.com to learn more.

Investor & Media Contact:
Alebund Pharmaceuticals
IR@alebund.com

View original content:https://www.prnewswire.com/news-releases/alebund-pharmaceuticals-announces-collaboration-and-license-agreement-with-r1-therapeutics-for-ap306-302715455.html

SOURCE Alebund Pharmaceuticals

FAQ

What did Alebund (DVA) license to R1 Therapeutics on March 17, 2026?

Alebund licensed exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China. According to the company, the agreement transfers commercial rights for the R1 Territory to R1 while retaining Alebund's China rights.

How much could Alebund (DVA) receive from the AP306 collaboration in milestone payments?

The agreement includes up to low triple‑digit millions of U.S. dollars in milestone payments. According to the company, payments cover development, regulatory, and commercial milestones in the licensed territory.

What royalty terms did Alebund (DVA) secure for AP306 sales in the R1 Territory?

Alebund will receive tiered royalties in the low double‑digit percent range on net sales. According to the company, royalties apply to AP306 sales in the territory outside Greater China.

Will Alebund (DVA) keep any equity or upside from R1 Therapeutics?

Yes. Alebund holds a substantial non‑dilutive equity interest in R1 with potential dividend upside. According to the company, this preserves Alebund's participation in R1's future commercial success.

Who will fund and lead AP306 clinical development under the collaboration announced March 17, 2026?

R1 Therapeutics will fund and lead global clinical development of AP306, with Alebund as a collaborative partner. According to the company, R1 will run the planned Phase 2b MRCT.

When will the global Phase 2b MRCT for AP306 begin according to Alebund (DVA)?

The companies plan to initiate a global Phase 2b MRCT in the U.S. and China later in 2026. According to the company, the trial start is expected to occur within the year of the March 17, 2026 announcement.